Literature DB >> 26577538

MicroRNA as Regulators of Cancer Stem Cells and Chemoresistance in Colorectal Cancer.

Xiaoming Liu, Qi Fu, Yong Du, Yinxue Yang1, William C Cho2.   

Abstract

Colorectal cancer (CRC) is one of the most common cancers worldwide. The development of resistance to anti-cancer treatment is one of the major challenges in the treatment of CRC, which limits the efficacy of both conventional and targeted therapies in clinical settings. Understanding the mechanisms underpinning resistances is therefore critical in developing novel agents to reverse drug resistance and for more specific targeted treatments. Accumulating studies have reported that microRNAs (miRNAs) are key players in the regulation of cancer cells with intrinsic/acquired drug resistance through varied mechanisms that endow cells with a drug-resistant phenotype. miRNAs have been evolved in the regulation of chemoresistance to various CRC treatments and the stemness of CRC stem cells (CRSCs), sequentially modulating the sensitivity of CRC cells to anti-cancer treatments. Targeting miRNAs may be a novel strategy for eradicating CRSCs, re-sensitizing drug-resistant cells to anti-cancer agents, improving drug efficiency and developing novel biological agents for CRC treatment. This paper highlights the role of miRNAs in the regulation of chemoresistance and CRSCs in CRC, with focus on the mechanisms underlying how miRNAs alter CRSCs fate, and the process of epithelial-to-mesenchymal transition, cell cycle and apoptosis in CRC cells.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26577538     DOI: 10.2174/1568009616666151118114759

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  18 in total

1.  Current Evidence on miRNAs as Potential Theranostic Markers for Detecting Chemoresistance in Colorectal Cancer: A Systematic Review and Meta-Analysis of Preclinical and Clinical Studies.

Authors:  Madhav Madurantakam Royam; Chellan Kumarasamy; Siddhartha Baxi; Ajay Gupta; Nachimuthu Ramesh; Gothandam Kodiveri Muthukaliannan; Rama Jayaraj
Journal:  Mol Diagn Ther       Date:  2019-02       Impact factor: 4.074

2.  Mucosal ribosomal stress-induced PRDM1 promotes chemoresistance via stemness regulation.

Authors:  Juil Kim; Yuseok Moon
Journal:  Commun Biol       Date:  2021-05-10

3.  Knockdown of miR-27a sensitizes colorectal cancer stem cells to TRAIL by promoting the formation of Apaf-1-caspase-9 complex.

Authors:  Rui Zhang; Jian Xu; Jian Zhao; Jinghui Bai
Journal:  Oncotarget       Date:  2017-07-11

4.  miR-495 sensitizes MDR cancer cells to the combination of doxorubicin and taxol by inhibiting MDR1 expression.

Authors:  Zhenyou Zou; Ruyi Zou; Dan Zong; Yonghong Shi; Jinyao Chen; Jie Huang; Jiahui Zhu; Liguan Chen; Xiaoyan Bao; Yuan Liu; Weihao Liu; Wenhui Huang; Jingsang Hu; Zhi Chen; Xiaojie Lao; Chaoqun Chen; Xiaoli Huang; Yao Lu; Xueyin Ni; Daoquan Fang; Dengqiang Wu; Shuangshuang Lu; Mingzhu Jiang; Chenyang Qiu; Yuya Wu; Qisha Qiu; Yanyuan Dong; Yangyang Su; Chenmin Zhao; Zhihe Zhong; Jing Cai; Yong Liang
Journal:  J Cell Mol Med       Date:  2017-04-14       Impact factor: 5.310

5.  miR-15b-5p resensitizes colon cancer cells to 5-fluorouracil by promoting apoptosis via the NF-κB/XIAP axis.

Authors:  Ci Zhao; Qi Zhao; Chunhui Zhang; Guangyu Wang; Yuanfei Yao; Xiaoyi Huang; Fei Zhan; Yuanyuan Zhu; Jiaqi Shi; Jianan Chen; Feihu Yan; Yanqiao Zhang
Journal:  Sci Rep       Date:  2017-06-23       Impact factor: 4.379

Review 6.  MicroRNA expression patterns and signalling pathways in the development and progression of childhood solid tumours.

Authors:  Anna L Leichter; Michael J Sullivan; Michael R Eccles; Aniruddha Chatterjee
Journal:  Mol Cancer       Date:  2017-01-19       Impact factor: 27.401

Review 7.  The Roles of Cancer Stem Cells and Therapy Resistance in Colorectal Carcinoma.

Authors:  Plabon Kumar Das; Farhadul Islam; Alfred K Lam
Journal:  Cells       Date:  2020-06-03       Impact factor: 6.600

Review 8.  MiR-29a: a potential therapeutic target and promising biomarker in tumors.

Authors:  Jin-Yan Wang; Qian Zhang; Dan-Dan Wang; Wei Yan; Huan-Huan Sha; Jian-Hua Zhao; Su-Jin Yang; He-da Zhang; Jun-Chen Hou; Han-Zi Xu; Yun-Jie He; Jia-Hua Hu; Shan-Liang Zhong; Jin-Hai Tang
Journal:  Biosci Rep       Date:  2018-02-08       Impact factor: 3.840

9.  C/EBPβ enhances platinum resistance of ovarian cancer cells by reprogramming H3K79 methylation.

Authors:  Dan Liu; Xiao-Xue Zhang; Meng-Chen Li; Can-Hui Cao; Dong-Yi Wan; Bi-Xin Xi; Jia-Hong Tan; Ji Wang; Zong-Yuan Yang; Xin-Xia Feng; Fei Ye; Gang Chen; Peng Wu; Ling Xi; Hui Wang; Jian-Feng Zhou; Zuo-Hua Feng; Ding Ma; Qing-Lei Gao
Journal:  Nat Commun       Date:  2018-04-30       Impact factor: 14.919

10.  Paclitaxel‑resistant gastric cancer MGC‑803 cells promote epithelial‑to‑mesenchymal transition and chemoresistance in paclitaxel‑sensitive cells via exosomal delivery of miR‑155‑5p.

Authors:  Mei Wang; Rong Qiu; Shaorong Yu; Xiaoyue Xu; Gang Li; Rongmin Gu; Caihong Tan; Wei Zhu; Bo Shen
Journal:  Int J Oncol       Date:  2018-10-22       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.